Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients [Yahoo! Finance]
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Yahoo! Finance
AUSTIN, Texas, April 08, 2024 BUSINESS WIRE Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived cfDNA (dd-cfDNA) test to detect rejection in adult and pediatric heart transplant recipients. These are the second and third peer-reviewed publications evaluating Natera's technology for use in heart transplantation. "We are encouraged by the results of these two prospective studies," said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera. "The consistent, excellent performance of Prospera Heart across multiple independent studies should inspire confidence among transplant physicians to leverage Prospera as part of standard patient care." The Prospera Heart test was launched in 2021 and received Medicare coverage following the 2022 publication of a multi-site clinical validation study, the DEDUCE study
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Natera to Report its First Quarter 2024 Results on May 9 [Yahoo! Finance]Yahoo! Finance
- Natera to Report its First Quarter 2024 Results on May 9Business Wire
- Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage [Yahoo! Finance]Yahoo! Finance
- Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg ShortageBusiness Wire
- Natera, Inc. (NASDAQ: NTRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
NTRA
Earnings
- 2/28/24 - Beat
NTRA
Sec Filings
- 5/1/24 - Form 4
- 5/1/24 - Form 4
- 5/1/24 - Form 4
- NTRA's page on the SEC website